Lv3
340 积分 2023-06-20 加入
The pancreatic cancer drug market
2天前
求助中
Pancreatic cancer
9天前
已完结
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
1个月前
已完结
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
2个月前
已完结
Pancreatic Adenocarcinoma
2个月前
已完结
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
2个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
3个月前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
3个月前
已完结
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine- based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
3个月前
已完结
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
3个月前
已完结
皖公网安备34019202002308
